Media News

The Norovirus Diagnostics Market to see digitization being devised at a CAGR of 8.4% from 2021-2031

Norovirus Diagnostics Market

The global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and is expected to exhibit a CAGR of around 8.4% between 2021-2031.

NEW YORK, UNITED STATES, May 9, 2022 /EINPresswire.com/ — The Norovirus Diagnostics Market is likely to grow immensely, at a CAGR of 8.4%. Physical health apps are gaining popularity. They are inclusive of calorie trackers, step-counters, and exercise and nutrition-based apps. These apps are to be at the forefront with regards to capitalizing on those having chronic ailments like high blood pressure, heart diseases, or diabetes. This would be a significant arm of the healthcare industry.

As per Persistence Market Research’s latest industry analysis, the global norovirus diagnostics market was valued at US$ 47.6 Mn in 2020, and is expected to exhibit a CAGR of around 8.4% over the forecast period (2021-2031).

The norovirus illness is highly contagious, and even a small amount of norovirus virions can induce infection (1-10 virions particles). Currently, only RT-PCR is available for virus detection, which is both, trustworthy and sensitive. However, carrying out these processes is time-consuming and necessitates the use of special equipment.

Hence, companies are focused on developing rapid point-of-care (POCT) tests such as biosensors or lateral flow immunoassays for norovirus detection. Increasing demand for rapid tests for the detection of norovirus is expected to propel market growth over the years to come.

Get Free Sample Copy of this Report@

Key market players are focusing on the development of new diagnostic tests to cater to rising demand in the market.

For Instance, in December 2020, Altona Diagnostics launched AltoStar Norovirus RT-PCR Kit 1.5. It is an automated in-vitro diagnostic test for the detection of norovirus genogroup I (GI) and II (GII).
The pandemic has had a significant impact on healthcare for conditions such as hypertension, cancer, diabetes management, and cardiovascular emergencies. Change in healthcare professionals’ focus away from these diseases and toward COVID-19 criticality has had a severe influence on the broader healthcare business. However, the market is expected to increase rapidly over the next years.

Company Profiles:

Abbott
R-Biopharm AG
Cepheid
Luminex Corporation
Meridian Bioscience
ELITechGroup
Biomerieux SA
CerTest Biotec S.L.
Elisabeth Pharmacon, Spol. S Ro
Qiagen
Altona Diagnostics GmbH
Eiken Chemical Co.

Request for Methodology@

Key Takeaways from Market Study

Based on product, rapid tests are leading with 56% market share due to their high accuracy and sensitivity.
Diagnostics laboratories dominate with a market share of 50%.
By region, North America is set to dominate the global market with a value share of around 32.6%.
Europe is slated to be the second-largest leading market with a value share of 29% across the forecast period.
In 2020, Japan dominated the East Asia market with 50%. However, over the forecasted period, the market in China is expected to grow exponentially at a CAGR of 14.1%.

“Increasing prevalence of norovirus infections and rising awareness about testing are expected to drive market growth over the next ten years,” says an analyst of Persistence Market Research.

Market Competition

Agreements, collaborations, and partnerships have emerged as key growth strategies adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

In August 2016, Danaher Corporation completed the acquisition of Cepheid, a molecular diagnostics company for approximately US$ 4 Bn.
In April 2020, Meridian Biosciences acquired Exalenz Bioscience for approximately US$ 89 Mn

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the norovirus diagnostics market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on product (rapid test kits, PCR kits, and ELISA-based kits), and end user (hospitals, diagnostics laboratories, and clinics), across seven key regions of the world.

Access Full Report@

Related Reports:

Infectious Diseases Diagnostics Market – Global market will reach a value worth US$ 876.6 Mn by 2016 end, up from US$ 827.7 Mn attained in 2015. The revenues are expected to reach US$ 1503.8 Mn by the end of 2024.

Infection Surveillance Solutions Market – Global infection surveillance solution market to increase from more than US$ 300 Mn in 2017 to about US$ 905 Mn by 2025 end, representing a CAGR of 14.04% from 2017-2025.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

Persistence Market Research Pvt. Ltd Atul Singh
PMR
+1 646-568-7751
email us here



Article originally published at https://www.einpresswire.com/article/571630731/the-norovirus-diagnostics-market-to-see-digitization-being-devised-at-a-cagr-of-8-4-from-2021-2031

This news story originally appeared at Media - Trend Magazine on 11 May 2022